To the content
3 . 2023
PDF

Mixed mold mycosis of the skin and soft tissues of the gluteal regions as a complication of lipofilling plastic surgery in an immunocompetent young patient (clinical case and literature review)

Abstract

The authors reviewed the literature data (PubMed resource) on the risk of complications of the lipofilling procedure, studied in detail the classification, pathogenesis, diagnostic methods and treatment algorithms for the two most dangerous types of invasive mold mycoses: aspergillosis and mucormycosis, as well as their combinations. A clinical example of the treatment of a patient with extensive invasive mycosis (aspergillosis + mucormycosis) of the pelvic girdle after lipofilling buttocks in the early postoperative period is given; the observation period was 1 year.

Keywords:lipofilling; complications of lipofilling; skin; invasive mycosis; aspergillosis; mucormycosis

Funding. The study had no sponsor support.

Conflict of interest. The authors declare no conflict of interest.

For citation: Obolensky V.N., Burova S.A., Chaparyan B.A., Fefelov S.A., Kashtanova A.A., Gorbacheva Yu.V. Mixed mold mycosis of the skin and soft tissues of the gluteal regions as a complication of lipofilling plastic surgery in an immunocompetent young patient (clinical case and literature review). Clinical and Experimental Surgery. Petrovsky Journal. 2023; 11 (3): 149–60. DOI: https://doi.org/10.33029/2308-1198-2023-11-3-149-160  (in Russian)


References

  1. Patient Alert: Gluteal Fat Grafting to the Buttocks is a High Risk Cosmetic Surgery Procedure Warns. New York, 2018. URL: https://www.premierphysicianmarketing.com/ (date of access September 20, 2020).
  2. Kim S.K., Choi J.A., Kim M.H., Kim M.S., Lee K.C. Treatment of the Mycobacterium chelonae Infection after fat injection. Arch Plast Surg. 2015; 42 (1): 68–72. DOI: https://doi.org/10.5999/aps.2015.42.1.68
  3. Rios L., Gupta V. Improvement in Brazilian Butt Lift (BBL) safety with the current recommendations from ASERF, ASAPS, and ISAPS. Aesthet Surg J. 2020; 40 (8): 864–70. DOI: https://doi.org/10.1093/asj/sjaa098
  4. Rakhimov A.Ya., Fayzullin T.R., Vasil’ev V.S., Sergeev I.V. Safety of lipophilization: mechanisms, methods of prevention and treatment of severe complications of injectable fat tissue transplantation. Plasticheskaya khirurgiya i esteticheskaya meditsina [Plastic Surgery and Aesthetic Medicine]. 2020; (4): 73–8. (in Russian)
  5. Vasilakis V., Hamade M., Stavrides S.A., Davenport T.A. Bilateral sciatic neuropathy following gluteal augmentation with autologous fat grafting. Plast Reconstr Surg Glob Open. 2018; 6 (3): e1696. DOI: https://doi.org/10.1097/GOX.0000000000001696
  6. Pek C.H., Lim J., Ng H.W., Lee H.J., Ong W.C., Foo A.T.L., et al. Extensive necrotizing fasciitis after fat grafting for bilateral breast augmentation: recommended approach and management. Arch Plast Surg. 2015; 42 (3): 365–7. DOI: https://doi.org/10.5999/aps.2015.42.3.365
  7. Skiada A., Lass-Floerl C., Klimko N., et al. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018; 56 (suppl 1): 93–101. DOI: https://doi.org/10.1093/mmy/myx101 PMID: 29538730.
  8. Tissot F., Agrawal S., Pagano L., et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017; 102 (3): 433–44. DOI: https://doi.org/10.3324/haematol.2016.152900 PMID: 28011902.
  9. Ullmann A.J., Aguado J.M., ArikanAkdagli S., et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018; 24 (suppl 1): e1–38. DOI: https://doi.org/10.1016/j.cmi.2018.01.002 PMID: 29544767.
  10. Shadrivova O.V., Hostelidi S.N., Chudinovskikh Yu.A., et al. Invasive aspergillosis and mucormycosis in oncohematological patients. Onkogematologiya [Oncohemotology]. 2018; 13 (2): 39–47. (on Russian)
  11. Kondaurova S.L., Begun I.V. Ultrasound imaging of manifestations of invasive mycosis (literature review and own clinical observations). Dermatovenerologiya. Kosmetologiya [Dermatovenerology. Cosmetology]. 2017, 3 (2): 193–208. (in Russian)
  12. Klimko N.N., Khostelidi S.N., Borzova Yu.V., et al. Invasive aspergillosis in children in St. Petersburg. Rossiyskiy zhurnal detskoy gematologii i onkologii [Russian Journal of Pediatric Hematology and Oncology]. 2014; (3): 37–43. (in Russian)
  13. Bonifaz A., Vázquez-González D., Tirado-Sánchez A., Ponce-Olivera R.M. Cutaneous zygomycosis. Clin Dermatol. 2012; 30: 413–9.
  14. Klimko N., Kozlova Y., Khostelidi S., et al. The burden of serious fungal diseases in Russia. Mycoses. 2015; 58 (S5): 58–62. DOI: https://doi.org/10.1111/myc.1238
  15. Taraskina A.E., Vasil’eva N.V., Pchelin I.M., Ignat’eva S.M., Spiridonova V.A., Uchevatkina A.E., et al. Molecular genetic methods for determining and species identification of fungi of the order Mucorales in accordance with global recommendations for diagnosis and therapy mucoromycosis (literature review). Problemy meditsinskoy mikologii [Problems of Medical Mycology]. 2020; 22 (1): 3–15. (in Russian)
  16. Reid G., Lynch J.P. III, Fishbein M.C., Clark N.M. Mucormycosis. Semin Respir Crit Care Med. 2020; 41 (1): 99–114.
  17. Jeong W., Keighley C., Wolfe R., Lee W., Slavin M., Kong D., et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019; 25 (1): 26–34. DOI: https://doi.org/10.1016/j.cmi.2018.07.011
  18. Cornely O.A., Alastruey-Izquierdo A., Arenz D., Chen S.C.A., Dannaoui E., Hochhegger B., et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019; 19 (12): e405–21. DOI: https://doi.org/10.1016/S1473-3099(19)30312-3
  19. Klimko N.N., Khostelidi S.N., Shadrivova O.V., et al. Invasive mucormycosis in oncohematological patients (results of a prospective study). Onkogematologiya [Oncohemotology]. 2017; 12 (2): 14–22. (in Russian)
  20. Pal R., Singh B., Bhadada S.K., Banerjee M., Bhogal R.S., Hage N., et al. COVID-19-associated mucormycosis: an updated systematic review of literature. Mycoses. 2021; 64 (12): 1452–9. DOI: https://doi.org/10.1111/myc.13338
  21. Didehdar M., Chegini Z., Khoshbayan A., Moradabadi A., Shariati A. Clinical presentations, diagnosis, management, and outcomes of renal mucormycosis: an overview of case reports. Front Med. 2022; 9: 983612.
  22. Sahu M., Shah M., Mallela V.R., Ingle A., Punjani T.A., et al. COVID-19 associated multisystemic mucormycosis from India: a multicentric retrospective study on clinical profile, predisposing factors, cumulative mortality and factors affecting outcome. Infection. 2023; 51 (2): 407–16.
  23. Amirzargar B., Jafari M., Ahmadinejad Z., Khodavaisy S., Zabihidan M., et al. Subglottic mucormycosis in a COVID-19 patient: a rare case report. Oxf Med Case Rep. 2022; 7: 274–7.
  24. Nepali R., Shrivastav S., Singh Shah D. Renal mucormycosis: post-COVID-19 infection presenting as unilateral hydronephrosis in a young immunocompetent male. Case Rep Nephrol. 2022; 2022: 3488031.
  25. Luo S., Huang X., Li Y., Wang J. Isolated splenic mucormycosis secondary to diabetic ketoacidosis: a case report. BMC Infect Dis. 2022; 22 (1): 596.
  26. Bauschert L., Sermet K., Fréalle E., Alfandari S., Beauvais D., et al. A case of subacute bowel obstruction revealing slowly-evolutive gastro-intestinal mucormycosis following allogeneic hematopoietic cell transplantation. J Med Mycol. 2022; 32 (4): 101312.
  27. Krishna V., Bansal N., Morjaria J., Kaul S. COVID-19-associated pulmonary mucormycosis. J Fungi (Basel). 2022; 8 (7): 711.
  28. Makarov A.A., Orazvaliev A.I., Ushakov R.V., Zhabko E.V. Clinical case of rhinoorbital-cerebral mucormycosis associated with COVID-19 and diabetes mellitus. Rossiyskaya rinologiya [Russian Rhinology]. 2022; 30 (3): 210–6. (in Russian)
  29. Swain S.K. Isolated involvement of palatine tonsil by COVID-19-asociated mcormycosis. Med J Dr D Y Patil Vidyapeeth. 2022; 15 (7): S110–3.
  30. Damaraju V., Agarwal R., Dhooria S., Aggarwal A.N., Muthu V., et al. Isolated tracheobronchial mucormycosis: report of a case and systematic review of literature. Mycoses. 2023; 66 (1): 5–12.
  31. Vikram V., Deshpande A., Reddy V., Pendyala S. COVID-19 – a consolidated review with emphasis on oral mucormycosis. JDMIMSU (Journal of Datta Meghe Institute of Medical Sciences University). 2022; 17 (5): S111–9.
  32. Shastri M., Raval D.M., Rathod V.M. Cerebral mucormycosis in context with COVID-19 infection. J Assoc Physicians India. 2022; 70 (8): 11–2.
  33. Ramani P., Krishnan R.P., Pandiar D., Ramalingam K., Gheena S., et al. Chronic invasive aspergillosis with fulminant mucormycosis sparing palate in a post-COVID-19 patient – a case report. Ann Maxillofac Surg. 2022; 12 (1): 102–5.
  34. Josefiak E.J., Foushee J.H., Smith L.C. Cutaneous mucormycosis. Am J Clin Pathol. 1958; 30 (6): 547–52. DOI: https://doi.org/10.1093/ajcp/30.6.547
  35. Rrapi R., Chand S., Gaffney R., Lo J.A., Smith J.S., Xia F.D., et al. Cutaneous mucormycosis arising in the skin folds of immunocompromised patients: a case series. JAAD Case Rep. 2021; 17: 92–5. DOI: https://doi.org/10.1016/j.jdcr.2021.06.022 PMID: 34746347; PMCID: PMC8551783.
  36. Simbli M., et al. Nosocomial post-traumatic cutaneous mucormycosis: a systematic review. Scand J Infect Dis. 2008; 40 (6–7): 577–82. DOI: https://doi.org/10.1080/00365540701840096 PMID: 18584552.
  37. Welch G., et al. Invasive cutaneous mucormycosis: a case report on a deadly complication of a severe burn. IDCases. 2022; 30: e01613. DOI: https://doi.org/10.1016/j.idcr.2022.e01613 PMID: 36131803; PMCID: PMC9483795.
  38. Devauchelle P., Jeanne M., Frealle E. Mucormycosis in burn patients. J Fungi (Basel). 2019; 5 (1): 25. DOI: https://doi.org/10.3390/jof5010025
  39. Shah Н., et al. Successful management of mucormycosis infection secondary to motor vehicle accident in a healthy adolescent: a case report. Med Mycol Case Rep. 2022; 38: 36–40.
  40. Colman S., et al. Hepatic failure and malnutrition as predisposing factors of cutaneous mucormycosis in a pediatric patient. Med Mycol Case Rep. 2021; 35: 26–9. DOI: https://doi.org/10.1016/j.mmcr.2021.12.005 PMID: 35059283; PMCID: PMC8760179.
  41. Liu J., Li S., Liu J., Liang B., Wang X., Wang H., et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020; 55: 102763.
  42. Song G., Liang G., Liu W. Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia. 2020; 185 (4): 599–606.
  43. Attaluri P., Soteropulos C., Kim N., Matloub H., Gander B. Cutaneous mucormycosis of the upper extremity: case reports highlighting rapid diagnosis and management. Ann Plast Surg. 2022; 89 (6): e18–20. DOI: https://doi.org/10.1097/SAP.0000000000003235 PMID: 36416689.
  44. Duffy J., Harris J., Gade L., Sehulster L., Newhouse E., O’Connell H., et al. Mucormycosis outbreak associated with hospital linens. Pediatr Infect Dis J. 2014; 33 (5): 472–6.
  45. Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., et al. Post-acute COVID-19 syndrome. Nat Med. 2021; 27 (4): 601–15.
  46. Castrejón Pérez A.D., Welsh E.C., Miranda I., Ocampo Candiani J., Welsh O., et al. Cutaneous mucormycosis. An Bras Dermatol. 2017; 92: 304–11.
  47. Mallis A., Mastronikolis S.N., Naxakis S.S., Papadas A.T. Rhinocerebral mucormycosis: an update. Eur Rev Med Pharmacol Sci. 2010; 14: 987–92.
  48. Kumar A., Kumar A., Kumar N., Sinha C., Singh P.K., et al. Does long-term oxygen therapy and noninvasive ventilation predispose rhino-orbital-cerebral mucormycosis in COVID-19 patients? Indian J Crit Care Med. 2022; 26 (9): 1063–4.
  49. Petrikkos G., Tsioutis C. Recent advances in the pathogenesis of mucormycoses. Clin Ther. 2018; 40 (6): 894–902.
  50. Prattes J., Wauters J., Giacobbe D.R., SalmantonGarcía J., Maertens J., Bourgeois M., et al. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients – a multinational observational study by the European Confederation of Medical Mycology. Clin Microbiol Infect. 2022; 28 (4): 580–7.
  51. Akhtar N., Khurshid Wani A., Kant Tripathi S., Prakash A., Amin-Ul Mannan M. The role of SARS-CoV-2 immunosuppression and the therapy used to manage COVID-19 disease in the emergence of opportunistic fungal infections: a review. Curr Res Biotechnol. 2022; 4: 337–49.
  52. Ibrahim A.S., Spellberg B., Walsh T.J., Kontoyiannis D.P. Pathogenesis of mucormycosis. Clin Infect Dis. 2012; 54 (suppl 1): S16–22.
  53. Lamoth F., Kontoyiannis D.P. Therapeutic challenges of non-aspergillus invasive mold infections in immunosuppressed patients. Antimicrob Agents Chemother. 2019; 63 (11): e01244-19.
  54. Ibrahim A.S., Gebremariam T., Lin L., Luo G., Husseiny M.I., Skory C.D., et al. The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol. 2010; 77 (3): 587–604.
  55. Ibrahim A.S. Host cell invasion in mucormycosis: role of iron. Curr Opin Microbiol. 2011; 14 (4): 406–11.
  56. Ibrahim A.S. Host-iron assimilation: pathogenesis and novel therapies of mucormycosis. Mycoses. 2014 Dec; 57 Suppl 3(0 3):13-7. doi: 10.1111/myc.12232. Epub 2014 Sep 1. PMID: 25178879; PMCID: PMC4461208.
  57. Santos R., Buisson N., Knight S., Dancis A., Camadro J.-M., Lesuisse E. Haemin uptake and use as an iron source by Candida albicans: role of CaHMX1-encoded haem oxygenase. Microbiology. 2003; 149 (3): 579–88.
  58. Boelaert J.R., de Locht M., Van Cutsem J., Kerrels V., Cantinieaux B., Verdonck A., et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest. 1993; 91 (5): 1979–86.
  59. Prakash H., Chakrabarti A. Global epidemiology of mucormycosis. J Fungi (Basel). 2019; 5 (1): 26.
  60. John T.M., Jacob C.N., Kontoyiannis D.P. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J Fungi (Basel). 2021; 7 (4): 298.
  61. Mitre-Aguilar I.B., Cabrera-Quintero A.J., Zentella-Dehesa A. Genomic and nongenomic effects of glucocorticoids: implications for breast cancer. Int J Clin Exp Pathol. 2015; 8 (1): 1–10.
  62. Ramamoorthy S., Cidlowski J.A. Corticosteroids: mechanisms of action in health and disease. Rheum Dis Clin. 2016; 42 (1): 15–31.
  63. Becker D.E. Basic and clinical pharmacology of glucocorticosteroids. Anesth Prog. 2013; 60 (1): 25–32.
  64. Russell C.D., Millar J.E., Baillie J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020; 395 (10 223): 473–5.
  65. Benhadid-Brahmi Y., Hamane S., Soyer B., Mebazaa A., Alexandre Alanio A., Chousterman B., et al. COVID-19-associated mixed mold infection: a case report of aspergillosis and mucormycosis and a literature review. J Med Mycol. 2022; 32: 101231.
  66. De Pauw B., Walsh T.J., Donnelly J.P., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008; 46 (12): 1813–21. DOI: https://doi.org/10.1086/588660
  67. Mohapatra S., Barik M.R., Rath S., Padhi R.K., Behera H.S., et al. Diagnostic performance and clinical utility of conventional PCR assay in early diagnosis of COVID-19 associated rhino-orbito-cerebral mucormycosis. J Fungi (Basel). 2022; 8 (8): 844.
  68. Skiada A., Lanternier F., Groll A.H., Pagano L., Zimmerli S., Herbrecht R., et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica. 2013; 98 (4): 492.
  69. Donnelly J.P., Chen S.C., Kauffman C.A., et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020; 71 (6): 1367–76. DOI: https://doi.org/10.1093/cid/ciz1008
  70. Roden M.M., Zaoutis T.E., Buchanan W.L., Knudsen T.A., Sarkisova T.A., Schaufele R.L., et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005; 41 (5): 634–53.
  71. Ostovan V.R., Tabrizi R., Bazrafshan H., Moghadami M., Grant M., et al. Mortality-related risk factors for coronavirus disease (COVID-19)-associated mucormycosis: a systematic review and meta-analysis. Curr Fungal Infect Rep. 2022; 16 (4): 143–53.
  72. Deutsch P.G., Whittaker J., Prasad S. Invasive and non-invasive fungal rhinosinusitis – a review and update of the evidence. Medicina. 2019; 55 (7): 319.
  73. Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2021; 42: 264.e5–8. DOI: https://doi.org/10.1016/j.ajem.2020.09.032
  74. Khostelidi S.N. Disseminated mucormycosis due to Lichtheimia ornata. Description of the clinical case and literature review. Problemy meditsinskoy mikologii [Problems of Medical Mycology]. 2021; 23 (1): 14–9. (in Russian)
  75. Burova S.A., Taganov A.V., Kashtanova A.A., Gorbacheva Yu.V. Mucormycosis – dangerous and real fungal superinfection during the COVID-19 pandemic. Chapter 2 – Focal and Invasive Mycoses. In: Medical Mycology Successes: Collection. 2022: XXIII: 51–4. (in Russian)
  76. Cornely O.A., Köhler P., Mellinghoff S.C., Klimko N. Mucormycosis 2018: the European Confederation for Medical Mycology (ECMM) method for assessing the quality of mucormycosis treatment. URL: ecmm.info/wp-content/uploads/EQUAL-Scorecard-Mucor-2018_Russian_20181031_DOI_QR.pdf DOI: https://doi.org/10.4126/FRL01-006409504
  77. Popova M.O., Rogacheva Yu.A. Mucormycosis: modern diagnostic and treatment capabilities, existing problems and new trends in therapy. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya [Clinical Microbiology and Antimicrobial Chemotherapy]. 2021; 23 (3): 226–38. (in Russian)
  78. Beeraka N.M., Liu J., Sukocheva O., Sinelnikov M.Y., Fan R. Antibody responses and CNS pathophysiology of mucormycosis in chronic SARS Cov-2 infection: current therapies against mucormycosis. Curr Med Chem. 2022; 29 (32): 5348–57.
  79. Shetty S.S., Shetty S., Venkatesh S.B Integrated treatment strategies and prosthetic rehabilitation for COVID-19-associated mucormycosis. J Datta Meghe Inst Med Sci Univ. 2022; 17 (5): S120–3.
  80. Abdelmonem R., Backx M., Vale L., Healy B., Williams D. Successful treatment of Mucor circinelloides in a Burn patient. Burns Open. 2022; 6 (2): 77–81.
  81. Höhl R., Bertram R., Kinzig M., Steinmann J., Sörgel F., et al. Isavuconazole therapeutic drug monitoring in critically ill ICU patients: a monocentric retrospective analysis. Mycoses. 2022; 65 (7): 747–52.
  82. Donnelley M.A., Zhu E.S., Thompson G.R. 3rd. Isavuconazole in the treatment of invasive aspergillos and mucormycosis infections. Infect Drug Resist. 2016; 9: 79–86.
  83. Van Daele R., Spriet I., Wauters J., Maertens J., Mercier T., Van Hecke S., et al. Antifungal drugs: what brings the future? Med Mycol. 2019; 57: S328–43.
  84. Burova S.A., Taganov A.V., Kashtanova A.A., Gorbacheva Yu.V. Mucormycosis of the skin in dermatological practice: dangerous co-infection during the COVID-19 pandemic (the current state of the issue). Rossiyskiy zhurnal kozhnykh i venericheskikh bolezney [Russian Journal of Skin and Venereal Diseases]. 2023; 26 (2): 131–42. DOI: https://doi.org/10.17816/dv278902 (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
CHIEF EDITOR
Sergey L. Dzemeshkevich
MD, Professor (Moscow, Russia)
Journals of «GEOTAR-Media»